a
Which Chemotherapy strategy is delivered BEFORE the main treatment, to make it easier to remove during surgery?
a) neoadjuvant
b) first line
c) second line
d) adjuvant
e) palliative
f) curative
d
Which Chemo strategy is delivered AFTER primary treatment; given to prevent possible reoccurrence?
a) neoadjuvant
b) first line
c) second line
d) adjuvant
e) palliative
f) curative
c
Which chemo strategy is also called salvage treatment?
a) neoadjuvant
b) first line
c) second line
d) adjuvant
e) palliative
f) curative
tumor agnostic
-molecular signatures or biomarkers used to select therapies regardless of tumor site of origin
microsatellite instability high (MSI-H)
-tumors that possess a molecular alteration that makes it difficult to repair damaged DNA; and produce abnormal proteins that make them easy to target
unresectable; MSI-H
Pembrolizumab or KEYTRUDA is indicated for adults and children with _________ & ________.
a
Which Cancer immunotherapy uses a patient's dendritic cells?
a) Sipuleucel
b) Ipilimumab
c) Belantamab
d) Daratumumab
e) Selinexor
a
Which Cancer immunotherapy is used to cause an immune response against cancer cells carrying the PAP antigen?
a) Sipuleucel
b) Ipilimumab
c) Belantamab
d) Daratumumab
e) Selinexor
antigen prostatic acid + GM-CSF
What are the components of Sipuleucel? (2)
a
Which cancer immunotherapy is indicated for prostate cancer?
a) Sipuleucel
b) Ipilimumab
c) Belantamab
d) Daratumumab
e) Selinexor
T-cell exhaustion
-progressive loss of T-cell function due to prolonged antigen stimulation
b
Which cancer immunotherapy is indicated for advanced metastatic melanoma?
a) Sipuleucel
b) Ipilimumab
c) Belantamab
d) Daratumumab
e) Selinexor
b
Which cancer immunotherapy can result in severe and fatal immune-mediated reactions like enterocolitis & hepatitis?
a) Sipuleucel
b) Ipilimumab
c) Belantamab
d) Daratumumab
e) Selinexor
CTLA-4 binds to B7; PD1 binds PDL1 or PDL2
T- cells can become unresponsive after what?
ipilimumab, novilumumab
What are our CLTA-4 blockers? (2)
Chmieric antigen Receptor therapy (CAR-T)
-genetic engineering of a patient’s T-cells to express fusion receptors with defined specificities for tumor-associated antigens
false; liquid only
CAR-T has been proven effective in "liquid" hematologic cancers and solid tumors. T/F?
leucel
-CAR-T therapeutics
cytokine release syndrome; ICANS
What are the most common adverse effects associated with CAR-T therapeutics? (2)
use an anti-IL-6 receptor antibody
How can we reverse Cytokine-Release syndrome?
ICANS
-a toxic encephalopathy with aphasia and confusion that develop into confusion and in severe cases to coma, seizures, motor weakness, and cerebral edema.
true
CRS and ICANS are both reversible. T/F?
b
Which will appear in the blood stream?
a) Lymphoma
b) Leukemia
a
Which is defined as a malignancy in both organs AND cells.
a) Lymphoma
b) Leukemia
b
Which is defined as a progressive/malignant disease of blood forming organs?
a) Lymphoma
b) Leukemia
Multiple Myeloma
-a tumor of antibody producing plasma cells in the bone marrow.
anemia, bone fracture, kidney failure, recurrent infection
What are common symptoms in Multiple Myeloma? (4)
increase in blood calcium, renal problems, anemia, bone damage
What does the CRAB criteria stand for?
melphalan
-a potent chemotherapy drug that kills cancer cells and also blood forming cells.
autologous stem cell transplant (asct)
-is the process of using a patient’s own (autologous) blood stem cells to help restore his or her blood supply and immune system
induction therapy, collection, freezing, high-dose chemo, thawing/infusion, engraftment/recovery
What is the ASCT treatment course in order? (6)
2; corticosteroid
Combination therapy with ______ treatment backbones and 1 _______ is generally used for treatment of myeloma.
bind to CRBN; activate ubiquitin ligase complex; transcription factors are targeted by proteasome
Lidomide MOA?
neutropenia, anemia, thrombocytopenia, infection
What are major adverse effects associated with Lidomides?
binds and activates apoptosis
Proteasome inhibitor MOA?
Bortezomib
-a proteasome inhibitor used IV; can cause peripheral neuropathy, neutropenia, anemia, thrombocytopenia
Ixazomib
- a proteasome inhibitor that is used orally; has similar SE's to Bortezomib except no peripheral neuropathy
revlimid; dexamethasone
_______ and _______ are used in combination with Ixazomib.
d
Which targets CD38 on MM cells to induce apoptosis?
a) Sipuleucel
b) Ipilimumab
c) Belantamab
d) Daratumumab
e) Selinexor
c
Which is an antibody conjugate indicated for patients who did not respond to at least 4 MM treatments?
a) Sipuleucel
b) Ipilimumab
c) Belantamab
d) Daratumumab
e) Selinexor
c
Which can cause ocular toxicity?
a) Sipuleucel
b) Ipilimumab
c) Belantamab
d) Daratumumab
e) Selinexor
e
Which medication is a small molecule drug that blocks XPO1 to cause accumulation in the nucleus?
a) Sipuleucel
b) Ipilimumab
c) Belantamab
d) Daratumumab
e) Selinexor